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INTRODUCTION
The results of clinical research on the treatment
of breast cancer have elucidated factors that pre-
dict the efficacy of a therapy, thus enabling individu-
alization of the therapeutic approach. In particular,
individualized regimens have been established for
patients who are positive for estrogen receptor (ER)
or progesterone receptor (PgR) and patients who
show overexpression of the c-erbB2 gene or its
products (also known as HER2/neu)(1-3). On the
other hand, there is no consensus regarding the
chemotherapy regimen for breast cancer, although
there have been reports of efficacy with regimens
including an anthracycline in patients who overex-
press HER2 (4). In addition, thymidine phosphory-
lase (TP), thymidylate synthase (TS) and dihydro-
pyrimidine dehydrogenase (DPD) have also been
studied as predictive factors for treatment with 5 -
fluorouracil (5 -FU) and its derivatives (5, 6). There
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are various methods for assay of those enzymes,
including quantitative determination of their activi-
ties, the reverse transcript-polymerase chain reac-
tion (RT-PCR) to determine the mRNA level and
immunohistochemical staining methods (7). Quan-
titative determination of the enzyme activity and RT-
PCR are the best methods for obtaining accurate
information regarding these enzyme activities, but
they require fresh samples and are technically com-
plicated. In contrast, the immunohistochemical stain-
ing method is technically simple, and although or-
dinary samples are sufficient for assay the results
are only qualitative.
In this study, we administered capecitabine, a
5 -FU derivative, monotherapy to Japanese patients
with advanced or recurrent breast cancer, performed
immunohistochemical staining on surgical speci-
mens and semi-quantitatively determined the ex-
pression levels of TP, TS and DPD by applying a
scoring method to the staining results (8). Then the
scores for the enzyme expression levels were ana-




During the period from September 2003 through
December 2006, 25 Japanese women with advanced
or recurrent breast cancer were administered cape-
citabine monotherapy at Tokushima Breast Care
Clinic. The clinical efficacy of the treatment in those
patients was able to be evaluated. The patients
consisted of three with advanced disease and 22
with recurrent disease. The capecitabine dosage
was 2,400 mg/day for a body surface area of 1.31
1.46 m2, 1,800 mg/day for a body surface area of
less than 1.31 m2 and 3,000 mg/day for an area of
greater than 1.46 m2. The clinical efficacy of the
treatment was assessed in accordance with the Gen-
eral Rules for Clinical and Pathological Recording of
Breast Cancer (15th Edition) (The Japanese Breast
Cancer Society)(9). The following clinicopathologi-
cal parameters were investigated for each of the
patients : the age, disease free interval (DFI), con-
tent of prior therapy, status of ER and PgR, and ex-
pression of HER2. The investigations of ER, PgR
and Her2 expressions and the assessment of the
findings were carried out by the conventional immu-
nohistochemical staining techniques.
We started this study after having got informed
consent in the word of mouth from each patient or
a family of a patient.
Immunohistochemical staining for TP, TS and DPD
Formalin-fixed, paraffin-embedded surgically
resected specimens were subjected to immunohis-
tochemical staining for each of TP, TS and DPD.
The respective primary antibodies used were 1C6 -
203, TS106 and 2H9-1b, and the conventional avidin-
biotin-peroxidase complex method was applied
(Table 1). The staining results were rated using a
four-stage scoring (14) system (8). That is, a score
of 1 was assigned in the case of no staining or stain-
ing of less than 25% of the observed cells. A score
of 2 was given to specimens for which there was
slight staining of at least 25% of the cells, while a
score of 3 was assigned to specimens showing weak
staining of at least 25% of the cells and a score of 4
was given to specimens showing strong staining
of at least 25% of the cells. TP staining is also ob-
served in the nucleus of cells, and thus both the nu-
cleus and cytoplasm were evaluated(Fig. 1). TS and
DPD are detected only in the cytoplasm, and thus
Table 1. Sources, dilution, pretreatment of antibodies used
Antibody Clone Manufacturer Dilution Pretreatment
TP 1C6-203 Chugai 1 : 500 autoclave
TS TS106 Quartett 1 : 25 autoclave
DPD 2H9-1b Chugai 1 : 100 autoclave
TP : Thymidine phosphorylase, DPD : Dihydropyrimidine de-
hydrogenase, TS : Thymidine synthase
Score 1 Score 2 Score 3 Score 4
Fig. 1 Immunohistochemical staining for TP. TP staining is also observed in the nucleus of cells, and thus both the nucleus and
cytoplasm were evaluated. That is, a score of 1 was assigned in the case of no staining or staining of less than 25% of the observed
cells. A score of 2 was given to specimens for which there was slight staining of at least 25% of the cells, while a score of 3 was as-
signed to specimens showing weak staining of at least 25% of the cells and a score of 4 was given to specimens showing strong stain-
ing of at least 25% of the cells.
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only the cytoplasm was evaluated for staining for
these enzymes.
Correlations between clinical response and expres-
sions of TP, TS and DPD
The clinical response of the patients and the
scores for the expressions of TP, TS and DPD, sin-
gly and in combination, i.e., TP/DPD, TP/TS and
TS/DPD, were analyzed for the presence of corre-
lations.
Statistical analyses
All data are expressed as meanSD. Comparison
of the clinical response to the capecitabine mono-
therapy and the patient background factors was per-
formed using chi-square test. The clinical response
of the patients and the scores for the enzyme ex-
pressions were analyzed for the presence of corre-




The age range of the patients was 3579 years
(mean : 5711.3 years), and the mean disease-free
interval (DFI) was 11 months. The sites of recur-
rence in the 23 patients with recurrent disease were
the lung in 5 patients, the liver in three patients, the
bones in 10 patients, the lymph nodes in 14 patients
(some patients had recurrence at multiple sites).
The overall results of the capecitabine monotherapy
showed a partial response (PR) in 5 patients, stable
disease (SD) in 9 patients (including 5 patients with
long SD of at least 6 months) and 11 patients with
progressive disease (PD). The overall response rate
(ORR) was 20% (5/25 patients), while the clinical
benefit (PR plus long SD cases) rate was 40% (10/
25 patients) (Table 2). Analysis of the therapeutic
efficacy as a function of the site of recurrence
showed one case of PR and 2 cases of SD in the 5
patients with recurrence in the lung. The 10 patients
with recurrences in the bones showed one case
of PR and 5 cases of SD, while 2 of the 3 patients
with recurrence in the liver showed SD. The results
in the 14 patients with recurrences in the lymph
nodes showed 3 cases of PR and 7 cases of SD.
Correlations between therapeutic efficacy and pa-
tient background factors
Stratification of the therapeutic efficacy as a func-
tion of the background factors found no difference
arising from the patients’ age. However, the DFI
was shorter in the patients showing PD compared
with in the patients achieving PR or SD. Almost all
of the patients had undergone chemoendocrine ther-
apy prior to enrollment in the present study. Four-
teen patients had been treated with taxan, and ap-
proximately half had shown a clinical benefit. In
addition, 6 patients had been treated with a 5 -FU de-
rivative, and more than half of those patients also
had shown a clinical benefit. Regardless of whether
or not hormone therapy had been administered
in the past, and the statuses for ER, PgR or Her2,
there were no correlations with the drug response
(Table 3).
Table 2. Clinical results in 25 patients with recurrent or ad-
vanced breast cancer treated capecitabine monotherapy.
Clinical results cases
Partial response (PR) 5
Stable disease (SD) 9
(long SD 5)
Progressive disease (PD) 11
Clinical response 5/25 (20%)
Clinical benefit (PR + long SD) 10/25 (40%)
Table 3. Correlations betweem therapeutic efficacy and patient background factors
Clinical response PR SD long SD PD
age 54.29.3 58.414.4 (53.215.2) 57.110
DFI 2919 2013 (1910) 1311
Previous treatment
anthracycline 4 4 3 9
taxan 4 3 3 7
5-FU 2 2 0 2
hormone therapy 4 7 4 8
ER (+) 3 6 3 6
(--) 2 3 2 5
PgR (+) 3 4 2 5
(--) 2 5 3 6
Her2(0-1) 2 6 3 7
(2-3) 2 3 2 3
PR : partial response, SD : stable disease, PD : progressive disease, DFI : disease free inferval, ER : estrogen receptor, PgR : proges-
terone receptor
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Correlations between therapeutic efficacy and TP,
TS and DPD scores
The therapeutic results were stratified as a func-
tion of the TP, TS and DPD scores. The TP score
showed a tendency to be higher in the PR and SD
patients compared with the PD patients, but the
differences were not statistically significant. The
TS score did not show any effect on the therapeu-
tic efficacy. The DPD score showed a tendency to
be lower in the PR patients compared with the SD
and PD patients, but again the differences were
not statistically significant (Table 4).
Correlations between therapeutic efficacy and com-
bined scores for TS/DPD, TP/DPD and TP/TS
The combined score for TS/DPD showed no cor-
relations with the drug response. Conversely, the
combined score for TP/DPD was significantly
higher in the order of PR, long SD and PD (Fig. 2).
The combined score for TP/TS showed higher in
the order of PR, long SD and PD, but there were no
statistically significant differences (Fig. 3).
DISCUSSION
Drugs for molecular-targeted therapy are being
developed for the treatment of cancers, and in com-
bination with proper selection of patients who are
likely to respond the trend is toward improved re-
sponse rates (1- 4). In the treatment of breast can-
cer, high efficacy has been achieved with chemo-
therapy regimens including anthracyclines and with
taxan, and these chemotherapy regimens are being
employed both prior to surgery and as postopera-
tive adjuvant chemotherapy (1). Other chemothera-
peutic agents that have been effective in the treat-
ment of breast cancer include vinorelbine and 5 -FU
derivatives, but they are generally used in patients
with recurrent disease. Capecitabine is a 5 -FU de-
rivative that was developed as a prodrug of 5’-deoxy-
5 -fluorouridine (5’-DFUR) (10 -12). It has been re-
ported that TP, TS and DPD are involved in the ac-
tivation/inactivation of 5 -FU and its derivatives and
are useful as factors in predicting the response of
breast cancer patients to those drugs. TP is an en-
zyme that converts capecitabine and 5’-DFUR into
5-FU, while TS interferes with DNA synthesis by
causing formation of a ternary complex between 5 -
fluorodeoxyuridine monophosphate (F -dUMP),
which is a metabolite of 5 -FU, and active folic acid.
DPD is an enzyme that inactivates 5 -FU. Accord-
ingly, in general, higher TP expression and lower
DPD expression inside tumors result in higher in-
tratumoral concentrations of 5 -FU and a more po-
tent antitumor effect (13 -15). It is also said that the
Fig. 3 Correlations between therapeutic efficacy and com-
bined scores for TP/TS. The combined score for TP/TS showed
higher in the order of PR, long SD and PD, but there were no sta-
tistically significant differences (PD vs PR : p=0.079).
Fig. 2 Correlations between therapeutic efficacy and com-
bined scores for TP/DPD. The combined score for TP/DPD
was significantly higher in the order of PR, long SD and PD
(PD vs PR : P0.01, PD vs long SD : P=0.05).
Table 4. Correlations between therapeutic efficacy and TP, TS,
DPD scores.
PR SD long SD PD
TP 3.0(2-4) 2.8(2-4) 2.0(2-4) 2.0(1-4)
TS 3.2(2-4) 3.4(3-4) 3.4(3-4) 3.3(2-4)
DPD 2.0(2-4) 2.6(1-3) 2.2(1-3) 2.4(1-3)
PR : partial response, SD : stable disease, PD : progressive dis-
ease, DFI : disease free inferval, ER : estrogen receptor, PgR :
progesterone receptor
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antitumor effect is greater when expression of TS
is low. Being able to quantitatively assay the ex-
pression or activity of TP, TS and DPD would have
a high level of clinical significance, but fresh bio-
logical samples are necessary for quantitative assay
(7, 16). Moreover, the available quantitative assays
are technically complicated and thus difficult for the
ordinary clinical facility to perform. In contrast, im-
munohistochemical staining techniques are com-
paratively simple. In the present study, we adminis-
tered capecitabine monotherapy to Japanese women
with advanced or recurrent breast cancer and in
whom the clinical efficacy was able to be evalu-
ated. In addition, surgically resected specimens
were subjected to immunohistochemical staining
for each of TP, TS and DPD, and the staining re-
sults were rated using a four-stage scoring system
in order to yield semiquantitative results (8). Finally,
the scores for those enzymes were analyzed for cor-
relations with the clinical efficacy results.
In the results of the clinical trials on patients with
recurrent breast cancer in Japan and other coun-
tries, high efficacy rates (30 - 40%) by capecitabine
monotherapy were observed (17).
In spite of the fact that most of the patients in-
cluded in this study had undergone previous treat-
ment with an anthracycline or taxan, capecitabine
monotherapy showed an ORR of 20% (5/25 pa-
tients), while the clinical benefit (PR plus long SD
cases) rate was 40% (10/25 patients). It has been
reported that the antitumor effect of capecitabine
is potentiated by combined administration with a
cytokine that induces intratumoral expression of TP
or with other antitumor drugs (11, 16). Combined
administration with taxan has been reported to be
particularly effective in this regard (11). In addition,
efficacy was observed even in patients previously
treated with another 5 -FU derivative. We surmise
that these good results were because capecitabine
is a drug that selectively increases the intratumoral
5 -FU concentration to a greater extent than occurs
with other 5 -FU derivatives (10 -12).
In this study, we analyzed the therapeutic effi-
cacy results for correlations with the semiquantita-
tive scores assigned to the expressions of each of
TP, TS and DPD. The TP score showed a tendency
to be higher in the PR and SD patients compared
with the PD patients, but the differences were not
statistically significant. The DPD score showed a
tendency to be lower in the PR patients compared
with the SD and PD patients, but again the differ-
ences were not statistically significant. These cor-
relations between the expressions of TP and DPD
and the therapeutic response are in agreement with
the results reported for the use of 5’-DFUR as post-
operative adjuvant therapy in breast cancer and co-
lon cancer patients (5, 14, 18, 19). With regard to
TS expression, it was reported that the clinical effi-
cacy of 5 -FU was good in pancreatic cancer patients
who showed low expression of TS (20), and it was
also reported that TS is an important prognostic
factor in other malignancies, such as colon cancer
(18, 21, 22). However, our present study found no
correlation between TS expression and the clinical
response of breast cancer. In addition, we were also
able to analyze the relationships of the combina-
tions of TP/DPD, TP/TS and TS/DPD to the clini-
cal response. Because we thought that a clearer re-
sult may be provided by comparing the ratio of the
each TP, DPD and TS. TP/DPD showed a signifi-
cant correlation, and TP/TS also showed a correla-
tion although it was not statistically significant.
These findings are in agreement with the reported
results for studies at the cellular level that the com-
bination of TP/DPD showed a higher correlation
with the therapeutic effect than either TP or DPD
alone (12). The number of patients in our study was
small, but our findings show that immunohisto-
chemical staining of patient surgical specimens to
elucidate the expressions of TP, TS and DPD indi-
cate the possibility of individualization of chemo-
therapy employing capecitabine. Further studies of
a larger number of patients are needed to estab-
lish the clinical significance of this approach, and
studies are also warranted with regard to the effec-
tiveness of induction of TP expression by use of cy-
tokines, anticancer drugs and other drugs such as
gefitinib (11, 16, 22, 23). The results of such stud-
ies can be thought to contribute to further improve-
ment of the efficacy of capecitabine.
CONCLUSION
Capecitabine monotherapy was effective in the
treatment of patients with advanced or recurrent
breast cancer. The expression score for the combi-
nation of TP/DPD showed a statistically significant
correlation with the clinical response, and the ex-
pression score for TP/TS also showed a correlation
although it was not statistically significant. These
findings indicate the potential for individualization
of the therapeutic approach.
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